

TECHNICAL BULLETIN

# pSP-*luc*+NF Fusion Vector

Instructions for Use of Product  
**E4471**



# pSP-*luc*+NF Fusion Vector

All technical literature is available at: [www.promega.com/protocols/](http://www.promega.com/protocols/)  
 Visit the web site to verify that you are using the most current version of this Technical Bulletin.  
 E-mail Promega Technical Services if you have questions on use of this system: [techserv@promega.com](mailto:techserv@promega.com)

|    |   |   |
|----|---|---|
| 1. | Description .....                               | 1 |
| 2. | Product Components and Storage Conditions ..... | 5 |
| 3. | Related Products .....                          | 6 |
| 4. | References.....                                 | 6 |
| 5. | Summary of Changes.....                         | 7 |

## 1. Description

The pSP-*luc*+NF Fusion Vector<sup>(a)</sup> is a luciferase cassette vector containing the engineered firefly luciferase gene, *luc*+NF. The *luc*+NF gene is related to the *luc*+ gene found in the pGL3 family of eukaryotic reporter vectors (1) but has been further modified for maximum flexibility in constructing N-terminal fusions (NF) with luciferase. The pSP-*luc*+NF Fusion Vector is not itself intended for the expression of luciferase in eukaryotic cells because it does not contain eukaryotic promoters, enhancers or polyadenylation signals.

The *luc*+NF gene is positioned downstream of an SP6 promoter and ribosome binding site. An opposing T7 promoter is located immediately downstream of *luc*+NF. Thus, the pSP-*luc*+NF Fusion Vector provides a convenient template for the in vitro synthesis of both sense and antisense luciferase transcripts for studies involving in situ hybridization, RNA processing, RNA transfection or coupled in vitro transcription/translation and protein folding. Multiple cloning regions containing recognition sequences for commonly used restriction enzymes are positioned at the 5' and 3' ends of *luc*+NF to provide maximum flexibility in cloning. Subcloning *luc*+NF into expression vectors provides a useful genetic reporter with exceptional sensitivity. Luciferase enzymatic activity can be assayed most efficiently using the Luciferase Assay System.

Luciferase is a 61kDa monomeric protein that does not require post-translational modifications for enzymatic activity. Thus, it can function as a genetic reporter immediately upon translation (2–4). Luciferase synthesized by in vitro translation can be labeled with <sup>35</sup>S, as the protein contains 4 cysteine and 14 methionine residues. To ensure full enzymatic activity of luciferase, no more than 5 codons can be deleted from either the 5' - or 3' -end of the coding region.



## Properties of the *luc*+NF Gene

The numerous modifications that distinguish *luc*+NF from the native luciferase gene are detailed in Table 1. Briefly, the *luc*+NF gene (and the related *luc*+ gene) contains four general classes of modifications: 1) The C-terminal tripeptide has been mutated to eliminate peroxisome targeting of the expressed protein; 2) codon usage was improved for expression in plant and animal cells; 3) two potential sites of N-glycosylation were removed; and 4) several DNA sequence changes were made to disrupt extended palindromes, remove internal restriction sites and eliminate consensus sequences recognized by genetic regulatory binding proteins (5), helping to ensure that the reporter gene itself is unaffected by spurious host transcriptional signals.

In addition, the *luc*+NF gene contains a unique BstEII restriction site inserted immediately downstream of the luciferase ATG translation start codon. The BstEII site allows a cloned insert to be positioned immediately downstream of the *luc*+NF initiation codon. If the cloned insert already contains an initiation codon, the *luc*+NF initiation sequences can be removed using BstEII and another restriction enzyme that cuts in the upstream multiple cloning region. This eliminates the possibility of expressing low levels of functional luciferase through internal initiation in the luciferase portion of the gene fusion.

As a result of the insertion of the BstEII site, the glutamic acid at position 2 of the native protein has been replaced with a valine-threonine at positions 2 and 3 of the *luc*+NF protein. Because of the altered N-terminal amino acid sequence, luciferase encoded by *luc*+NF may exhibit slightly lower enzymatic activity than that encoded by *luc*+.

**Note:** The numbering scheme for amino acids is relative to the first amino acid, Met #1, of luciferase (*luc*). The numbering of nucleotides is relative to the first base, "A", of the luciferase open reading frame. All numberings for Table 1 refer to the amino acid or nucleic acid positions for the native luciferase gene. Because of the addition of the BstEII site at position 4 of the native nucleic acid sequence to create *luc*+NF, all of the nucleic acid numbering will be shifted by 3 nucleotides and all amino acid numbering will be shifted by 1 residue for the *luc*+NF gene.

**Table 1. Summary of Modifications in the *luc*+NF Gene.**

| <b>Purpose of Modification</b>  | <b>Sequence Modification in <i>luc</i>+NF</b> |                            |                           |                           |                         |                         |
|---|---|----------------------------|---------------------------|---------------------------|-------------------------|-------------------------|
| Introduce NcoI and BstEII sites for the construction of N-terminal fusions with <i>luc</i> +NF. | <i>luc</i> :                                  | AAA                        | Met <sub>1</sub><br>ATG   | Glu <sub>2</sub><br>GAA   | Asp <sub>3</sub><br>GAC |                         |
|   | <i>luc</i> +NF:                               | TCC                        | Met <sub>1</sub><br>ATG   | Val <sub>2</sub><br>GTC   | Thr <sub>3</sub><br>ACC | Asp <sub>4</sub><br>GAC |
|   |   |                            | NcoI                      |                           | BstEII                  |                         |
| Remove internal XbaI site; disrupt extended palindrome.   | #50   |                            | XbaI                      |                           |                         |                         |
|   | <i>luc</i> :                                  | CTCTAGAGG                  |                           |                           |                         |                         |
| <i>luc</i> +NF:   | CGCTGGAAG                                     |                            |                           |                           |                         |                         |
| Eliminate potential glycosylation and ATF sites.  | <i>luc</i> :                                  | Asn <sub>51</sub><br>AAC   | Ile <sub>52</sub><br>ATC  | Thr <sub>53</sub><br>ACG  | TACGCGGAA               |                         |
|   | <i>luc</i> +NF:                               | Asp <sub>51</sub><br>GAC   | Ile <sub>52</sub><br>ATC  | Thr <sub>53</sub><br>ACT  | TACGCTGAG               |                         |
| Eliminate potential glycosylation sites.  | <i>luc</i> :                                  | Asn <sub>120</sub><br>AAC  | Ile <sub>121</sub><br>ATT | Ser <sub>122</sub><br>TCG |                         |                         |
|   | <i>luc</i> +NF:                               | Gly <sub>120</sub><br>GGC  | Ile <sub>121</sub><br>ATT | Ser <sub>122</sub><br>TCG |                         |                         |
| Remove potential TGT-3 site; improve codon usage.   | #376  |                            |                           |                           |                         |                         |
|   | <i>luc</i> :                                  | GTAGTGTITGTT               |                           |                           |                         |                         |
| <i>luc</i> +NF:   | GTGGTGTTCGTT                                  |                            |                           |                           |                         |                         |
| Improve codon usage.  | #429  |                            |                           |                           |                         |                         |
|   | <i>luc</i> :                                  | ATTACCAATAATCCAG           |                           |                           |                         |                         |
| <i>luc</i> +NF:   | GCTCCCAATCATCCAA                              |                            |                           |                           |                         |                         |
| Improve codon usage.  | #549  |                            |                           |                           |                         |                         |
|   | <i>luc</i> :                                  | ACCAGAGTCCTTTGATCGTGACAAA  |                           |                           |                         |                         |
| <i>luc</i> +NF:   | GCCAGAGTCCTTCGATAGGGACAAG                     |                            |                           |                           |                         |                         |
| Remove internal EcoRI site, improve codon usage.  | #586  |                            | EcoRI                     |                           |                         |                         |
|   | <i>luc</i> :                                  | ATAATGAATTCC               |                           |                           |                         |                         |
| <i>luc</i> +NF:   | ATCATGAACTCC                                  |                            |                           |                           |                         |                         |
| Remove internal BstEII site and potential AP-2 and LF-A1 sites; improve codon usage.            | #611  |                            | BstEII                    |                           |                         |                         |
|   | <i>luc</i> :                                  | GGTTACCTAAGGGTGTGGCCCTTCGG |                           |                           |                         |                         |
| <i>luc</i> +NF:   | GTCTGCCTAAAGGTGTGCGCTCTGCCT                   |                            |                           |                           |                         |                         |
| Remove potential AP-1 site.   | #649  |                            |                           |                           |                         |                         |
|   | <i>luc</i> :                                  | TGCGTCAG                   |                           |                           |                         |                         |
| <i>luc</i> +NF:   | TGCGTGAG                                      |                            |                           |                           |                         |                         |


**Table 1. Summary of Modifications in the *luc*+NF Gene (continued).**

| <b>Purpose of Modification</b>                          | <b>Sequence Modification in <i>luc</i>+NF</b> |                                 |                    |                    |                    |                    |      |
|---|---|---------------------------------|--------------------|--------------------|--------------------|--------------------|------|
|   | #823  |                                 |                    |                    |                    |                    |      |
| Improve codon usage.                                    | <i>luc</i> :                                  | TTACGATCCCTTCAGGATTACAAA        |                    |                    |                    |                    |      |
|   | <i>luc</i> +NF:                               | CTGAGGAGCCTTCAGGATTACAAG        |                    |                    |                    |                    |      |
|   | #859  |                                 |                    |                    |                    |                    |      |
| Improve codon usage.                                    | <i>luc</i> :                                  | TTGCTAGTACCAACCCTATTTTCA        |                    |                    |                    |                    |      |
|   | <i>luc</i> +NF:                               | CTGCTGGTGCCAACCCTATTCTCC        |                    |                    |                    |                    |      |
|   | #948  |                                 |                    |                    |                    |                    |      |
| Eliminate internal palindrome;<br>improve codon usage.  | <i>luc</i> :                                  | GGGCGCACCTCTTTCGAAA             |                    |                    |                    |                    |      |
|   | <i>luc</i> +NF:                               | TGGCGCTCCCCTCTCTAAG             |                    |                    |                    |                    |      |
|   | #987  |                                 |                    |                    |                    |                    |      |
| Improve codon usage.                                    | <i>luc</i> :                                  | AAAACGCTTCCATCTTCCAGGGATACGA    |                    |                    |                    |                    |      |
|   | <i>luc</i> +NF:                               | CAAGAGGTCCATCTGCCAGGTATCAGG     |                    |                    |                    |                    |      |
|   | #1161   |                                 |                    |                    |                    |                    |      |
| Eliminate potential AP-1 site;<br>improve codon usage.  | <i>luc</i> :                                  | GAGAGGCGAATTATGTGTCTCAGAGGA     |                    |                    |                    |                    |      |
|   | <i>luc</i> +NF:                               | AAGAGGCGAACTGTGTGTGAGAGGT       |                    |                    |                    |                    |      |
|   | #1305   |                                 |                    |                    |                    |                    |      |
| Eliminate palindrome structure;<br>improve codon usage. | <i>luc</i> :                                  | AGTTGACCGCTTGAAGTCTTTAATTAATAAC |                    |                    |                    |                    |      |
|   | <i>luc</i> +NF:                               | CGTTGACCGCTTGAAGTCTCTGATTAAGTAC |                    |                    |                    |                    |      |
|   | #1336   | EcoRV                           |                    |                    |                    |                    |      |
| Remove internal EcoRV site;<br>improve codon usage.     | <i>luc</i> :                                  | AAAGGATATCAGGTGGCC              |                    |                    |                    |                    |      |
|   | <i>luc</i> +NF:                               | AAAGGCTATCAGGTGGCT              |                    |                    |                    |                    |      |
|   | #1368   | ClaI                            |                    |                    |                    |                    |      |
| Remove internal ClaI site;<br>improve codon usage.      | <i>luc</i> :                                  | ATCGATATTGTTA                   |                    |                    |                    |                    |      |
|   | <i>luc</i> +NF:                               | ATCCATCTTGCTC                   |                    |                    |                    |                    |      |
|   | #1403   |                                 |                    |                    |                    |                    |      |
| Remove potential SP-1 site<br>and AP-2 sites.           | <i>luc</i> :                                  | CGGGCGTGCC                      |                    |                    |                    |                    |      |
|   | <i>luc</i> +NF:                               | CAGGTGTCGC                      |                    |                    |                    |                    |      |
|   |   | Gly <sub>547</sub>              | Lys <sub>548</sub> | Ser <sub>549</sub> | Lys <sub>550</sub> | Leu <sub>551</sub> | stop |
| Remove peroxisome<br>targeting sequence.                | <i>luc</i> :                                  | GGA                             | AAG                | TCC                | AAA                | TTG                | TAA  |
|   | <i>luc</i> +NF:                               | Gly <sub>547</sub>              | Lys <sub>548</sub> | Ile <sub>549</sub> | Ala <sub>550</sub> | Val <sub>551</sub> | stop |
|   |   | GGA                             | AAG                | ATC                | GCC                | GTG                | TAA  |

## 2. Product Components and Storage Conditions

| PRODUCT                           | SIZE | CAT.# |
|-----------------------------------|------|-------|
| pSP- <i>luc</i> +NF Fusion Vector | 20µg | E4471 |


**Storage Conditions:** Store the pSP-*luc*+NF Fusion Vector at -20°C.



**Figure 1. pSP-*luc*+NF Fusion Vector circle map and sequence reference points.**  
(rbs = ribosome binding site)

### Sequence reference points:

|   |           |
|---|-----------|
| SP6 RNA polymerase initiation site            | 1         |
| upstream multiple cloning region              | 11–53     |
| luciferase coding region                      | 45–1700   |
| downstream multiple cloning region            | 1702–1731 |
| T7 RNA polymerase promoter (-17 to +3)        | 1740–1759 |
| T7 RNA polymerase initiation site             | 1742      |
| ColE1-derived replication origin              | 2014      |
| β-lactamase (Amp <sup>r</sup> ) coding region | 3636–2776 |
| SP6 RNA polymerase promoter (-17 to +3)       | 4087–3    |



**Figure 2. pSP-*luc*+NF Fusion Vector promoter and multiple cloning region sequence.** The sequence shown corresponds to RNA synthesized by SP6 RNA polymerase and corresponds to the sequence of *luc*+NF mRNA. Note that cleavage at the ClaI site is blocked when the pSP-*luc*+NF Fusion Vector is propagated in host strains containing *dam* methylase activity.

### 3. Related Products

| Product   | Size         | Cat.# |
|---|--------------|-------|
| Luciferase Assay System (with Cell Culture Lysis Reagent) | 100 assays   | E1500 |
| Luciferase Assay System with Reporter Lysis Buffer        | 100 assays   | E4030 |
| Luciferase Assay Reagent 10-Pack                          | 1,000 assays | E1501 |
| Luciferase Assay Reagent (bulk liquid reagent)            | 100ml        | E1483 |
| pGL3-Control Vector                                       | 20µg         | E1741 |
| pGL3-Enhancer Vector                                      | 20µg         | E1771 |
| pGL3-Promoter Vector                                      | 20µg         | E1761 |
| pGL3-Basic Vector   | 20µg         | E1751 |

### 4. References

1. Sherf, B. and Wood, K.V. (1994) Increased expression and convenience with the new pGL3 Luciferase Reporter Vectors. *Promega Notes* **49**, 14–21.
2. Ow, D. *et al.* (1986) Transient and stable expression of the firefly luciferase gene in plant cells and transgenic plants. *Science* **234**, 856–9.
3. deWet, J.R. *et al.* (1987) Firefly luciferase gene: Structure and expression in mammalian cells. *Mol. Cell Biol.* **7**, 725–37.
4. Wood, K.V. (1990) Firefly luciferase: A new tool for molecular biologists. *Promega Notes* **28**, 1–3.
5. Faisst, S. and Meyer, S. (1992) Compilation of vertebrate-encoded transcription factors. *Nucleic Acids Res.* **20**, 3–26.

## 5. Summary of Changes

The following changes were made to the 11/15 revision of this document:

1. The patent information was updated to remove expired statements.
2. The document design was updated.

### <sup>(e)</sup>READ THIS FIRST BEFORE OPENING PRODUCT

BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE TERMS OF THIS LIMITED USE LABEL LICENSE. If the researcher is not willing to accept the terms of this label license, and the product is unused, Promega will accept return of the unused product and provide the researcher with a full refund.

Researchers may use this product for research use only, no commercial use is allowed. "Commercial use" means any and all uses of this product and derivatives by a party for money or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research. Researchers shall have no right to modify or otherwise create variations of the nucleotide sequence of the luciferase gene except that researchers may: (1) create fused gene sequences provided that the coding sequence of the resulting luciferase gene has no more than four deoxynucleotides missing at the affected terminus compared to the intact luciferase gene sequence, and (2) insert and remove nucleic acid sequences in splicing research predicated on the inactivation or reconstitution of the luminescence of the encoded luciferase. No other use or transfer of this product or derivatives is authorized without the prior express written consent of Promega. In addition, researchers must either: (1) use luminescent assay reagents purchased from Promega for all determinations of luminescence activity of this product and its derivatives; or (2) contact Promega to obtain a license for use of the product and its derivatives. Researchers may transfer derivatives to others for research use provided that at the time of transfer a copy of this label license is given to the recipients and recipients agree to be bound by the terms of this label license. With respect to any uses outside this label license, including any diagnostic, therapeutic or prophylactic uses, please contact Promega for supply and licensing information. PROMEGA MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING FOR MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH REGARDS TO THE PRODUCT. The terms of this label license shall be governed under the laws of the State of Wisconsin, USA. This label license relates to Promega patents and/or patent applications on improvements to the luciferase gene. © 1994–2015 Promega Corporation. All Rights Reserved.

Products may be covered by pending or issued patents or may have certain limitations. Please visit our Web site for more information.

All prices and specifications are subject to change without prior notice.

Product claims are subject to change. Please contact Promega Technical Services or access the Promega online catalog for the most up-to-date information on Promega products.